Abstract

BackgroundKinase insert domain-containing receptor (KDR) plays a critical role in the metastasis of cancer and is used as a molecular target in cancer therapy. We investigated the characteristics of the -271 G>A polymorphism of the KDR gene to gain information that may benefit the development of individualized therapies for patients with non-small cell lung cancer (NSCLC).MethodsThe -271 G>A polymorphism of the KDR gene in 106 lung cancer patients and 203 healthy control individuals was analyzed by polymerase chain reaction (PCR) and DNA sequencing methods. Real-time quantitative PCR and immunohistochemical methods were used to evaluate KDR mRNA and protein expression levels, respectively, in frozen tumor specimens.ResultsThe -271 G>A polymorphism was associated with the mRNA expression level of the KDR gene in tumor tissues (t = 2.178, P = 0.032, independent samples t-test). Compared with the AG/GG genotype, the AA genotype was associated with higher KDR mRNA expression in tumor tissues. We found no relationship between the genotype and the KDR protein expression level and no significant difference in the distribution of the KDR gene polymorphism genotypes between lung cancer patients and the control group (χ2 = 1.269, P = 0.264, Fisher's exact test).ConclusionThis study is the first to show that the -271 G>A polymorphism of the KDR gene may be a functional polymorphism related to the regulation of gene transcription. These findings may have important implications for therapies targeting KDR in patients with NSCLC.

Highlights

  • Kinase insert domain-containing receptor (KDR) plays a critical role in the metastasis of cancer and is used as a molecular target in cancer therapy

  • The kinase insert domain-containing receptor (KDR; known as vascular endothelial growth factor receptor 2: VEGFR-2) gene plays a critical role in cancer metastasis and is used as a molecular target in cancer therapy [9,10,11]

  • Ours is the first study to assess the relationship between the -271 G>A polymorphism of KDR and KDR mRNA and protein expression in non-small cell lung cancer (NSCLC) patients

Read more

Summary

Introduction

Kinase insert domain-containing receptor (KDR) plays a critical role in the metastasis of cancer and is used as a molecular target in cancer therapy. We investigated the characteristics of the -271 G>A polymorphism of the KDR gene to gain information that may benefit the development of individualized therapies for patients with non-small cell lung cancer (NSCLC). Angiogenesis is an essential process in the development, growth, and metastasis of malignant tumors, including lung cancer tumors. The kinase insert domain-containing receptor (KDR; known as vascular endothelial growth factor receptor 2: VEGFR-2) gene plays a critical role in cancer metastasis and is used as a molecular target in cancer therapy [9,10,11]. Little is known about its polymorphisms and the functional significance of its association with lung cancer

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call